Drug Type Small molecule drug |
Synonyms + [4] |
Mechanism HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H28CaFN3O6S |
InChIKeyAVDMILNVMOXCHF-DHMAKVBVSA-N |
CAS Registry147098-20-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperlipidemias | Phase 3 | KR | 06 Jul 2017 | |
Diabetes Mellitus, Type 2 | Phase 3 | KR | 04 Nov 2015 | |
Dyslipidemias | Phase 3 | KR | 04 Nov 2015 | |
Diabetes Mellitus | Phase 3 | KR | 01 Jun 2013 |
Not Applicable | 102 | wmxpfcpavv(ckzkzylghp) = tgmskhuvxw gymqtrvuys (ltwbrrnuty ) | Positive | 01 Feb 2014 | |||
Not Applicable | - | (Sham-operated) | xjxxvobkdm(njbkxsknxg) = IgG extravasation nfbjhrcvfd (uabkelhimw ) | - | 01 Feb 2013 | ||
SAH+vehicle |